drugset
Drugs / rAd26-S
last change Jul 2022 re-read 2 minutes ago

rAd26-S

Vaccine

Developed for
COVID-19
Investigated by
AstraZeneca · R-Pharm · Russian Direct Investment Fund · The Gamaleya National Center of Epidemiology & Microbiology

Trials 3 · a red edge is where a trial was stopped

today NCT04684446 · Ph 1/2 NCT04760730 · Ph 1/2 NCT04686773 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/22 trials
Phase 1/2 NCT04684446 Sep → Nov 2021 COVID-19 R-Pharm Completed No outcome recorded
Phase 1/2 NCT04760730 Jul 2021 → Mar 2022 COVID-19 R-Pharm Completed No outcome recorded
Phase 21 trial
Phase 2 NCT04686773 Mar → Oct 2021 COVID-19 R-Pharm Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as rAd26-S ClinicalTrials.gov intervention name — accepted as the source's own label NCT04686773 ↗
2

NCT04684446 ↗

NCT04760730 ↗
Modality Vaccine “heterologous booster vaccine containing combination of AZD1222 and rAd26-S” NCT04686773 ↗
Route Intramuscular “1 IM injection of rAd26-S on Day 1 followed by AZD1222 on Day 29” NCT04684446 ↗